If you make a baby lotion, a bath oil or a nappy cream for the EU market, the safety file behind it is held to a higher standard than the same document for an adult product. A CPSR for baby cosmetics has to answer a harder question: is this formula safe not just for skin in general, but for the thin, permeable, still-developing skin of an infant who weighs a fraction of an adult and cannot tell you when something stings? This article explains why products for children — especially those under three — attract the strictest assessment, what Regulation (EC) No 1223/2009 actually requires in the safety report, which ingredients you should restrict or avoid, how nappy creams can drift into borderline territory, and exactly what extra data your safety assessor will ask for before signing.
None of this makes baby products impossible to place on the market. It means the margins are tighter and the supporting data more complete — and getting that right at the formulation stage is far cheaper than discovering a problem after a batch is made.
Key takeaways
- Infant skin is thinner and more permeable, and a baby’s high surface-area-to-bodyweight ratio means the same applied dose produces higher systemic exposure per kilogram — so the Margin of Safety is calculated far more conservatively.
- Annex I of Regulation (EC) No 1223/2009 requires the CPSR to give specific consideration to products intended for children under 3, both in the exposure assessment and in microbiological quality.
- Several preservatives and other substances carry explicit “not for children under three” restrictions in the Annexes; fragrance, essential oils and known allergens should be minimised or avoided.
- Nappy and diaper creams raise occlusion and barrier questions and can sit on the borderline with medicinal or biocidal products depending on their claims.
- Baby products need the most demanding microbiological limits, preservative-efficacy (challenge) testing, and documented dermatological and ocular tolerance data.
Why infant skin changes the safety maths
The reason a baby product is assessed more strictly is physiological, not bureaucratic. A newborn’s skin barrier — the stratum corneum — is thinner and less mature than an adult’s, its pH and hydration behave differently, and it is more permeable. That means a higher proportion of what you apply can be absorbed through the skin rather than staying on its surface.
Two things then compound the problem. First, infants have a much higher surface-area-to-bodyweight ratio than adults: relative to how much they weigh, there is far more skin, so the same amount of product spread over the same area delivers a considerably higher systemic dose per kilogram of bodyweight. Second, an infant’s liver and kidneys are immature, so the capacity to break down and clear an absorbed substance is reduced. More goes in, and less comes out. The assessor therefore cannot reuse adult assumptions — the whole toxicological picture is recalculated for a smaller, more absorbent, less resilient user.
What the CPSR must prove for children under three
The Cosmetic Product Safety Report is the mandatory safety dossier every EU cosmetic needs — Part A gathers the safety information and Part B is the assessor’s reasoned conclusion under Article 10. If you want the fundamentals first, our CPSR Explained guide walks through both parts, and How to Get a CPSR for Your Cosmetic Product covers the practical process.
Annex I singles out the vulnerable user in two important places. In the exposure assessment (Part A), the target population must be taken into account, so a product intended for infants must be assessed against infant exposure — realistic amounts applied, frequency of use, body areas and, crucially, an appropriate low bodyweight. And in the microbiological quality section, Annex I specifically directs particular attention to products used on children under three years of age (alongside products for the eye area, mucous membranes and compromised skin).
How the Margin of Safety gets more conservative
The core calculation is the Margin of Safety (MoS): the ratio of a substance’s No-Observed-Adverse-Effect Level to the estimated systemic exposure dose (MoS = NOAEL ÷ SED). A MoS of at least 100 is generally taken as the threshold for acceptable safety. The SCCS — the EU’s Scientific Committee on Consumer Safety — publishes the Notes of Guidance that assessors follow, including default values such as a 60 kg adult bodyweight and standard dermal-absorption and retention assumptions.
For a baby product, those defaults shift towards caution. A far lower bodyweight and a higher relative applied amount push the systemic exposure dose up, which drives the Margin of Safety down for exactly the same formula. Where data on dermal absorption or early-life toxicology is limited, the assessor may add further uncertainty factors. In practice, an ingredient level that is comfortable in an adult moisturiser can fail the MoS test in an infant lotion — so concentrations often have to come down.
Note: “Under three” is a specific regulatory bracket, not a marketing phrase. If your product is intended, labelled or reasonably foreseeably used on children under three, the stricter Annex I considerations apply even if you did not set out to make a “baby” range.
Restricted and best-avoided ingredients in baby cosmetics
Beyond the exposure maths, the Annexes to Regulation (EC) No 1223/2009 contain restrictions that specifically target young children. Several preservatives and other substances carry a condition along the lines of “not to be used in products for children under three years of age,” sometimes with narrow exceptions for rinse-off items. Iodopropynyl butylcarbamate and salicylic acid are well-known examples of substances whose entries restrict or exclude use in the under-three group. Your assessor checks every ingredient against Annexes II–VI at the concentration you actually use.
Good formulation practice for baby cosmetics goes further than the legal minimum:
- Fragrance and essential oils: minimise or avoid them. Fragrance is a leading cause of skin sensitisation, and many essential oils are naturally rich in regulated allergen constituents. Under Regulation (EU) 2023/1545, the expanded list of named fragrance allergens must be declared on the label above the usual thresholds — a strong reason to keep baby formulas fragrance-light or fragrance-free.
- Known allergens and sensitisers: favour ingredients with a clean toxicological history and avoid strong sensitisers, dyes and unnecessary botanicals.
- Preservative choice: you still must preserve the product adequately (see below), so the aim is a well-tolerated preservative system that is permitted for the age group and used at the lowest effective level.
Warning: “Natural” and “essential-oil-based” are not shortcuts to a gentler safety profile. Essential oils can contain high levels of sensitising allergen molecules, and a poorly preserved “natural” baby product is a microbiological risk on the most vulnerable skin. Every botanical still has to pass the same Margin of Safety and allergen assessment.
Nappy and diaper creams: occlusion and the borderline trap
Nappy creams deserve their own attention for two reasons. First, occlusion: a barrier cream sits under a nappy for hours, often on skin that is already damaged or inflamed. Occlusion and compromised skin both increase absorption, so the exposure assessment has to assume worse-case penetration, not best-case.
Second, claims can push a nappy cream over a legal boundary. A product presented purely to protect, soften or maintain the skin is a cosmetic. But if it is presented to treat or prevent a condition such as nappy-rash dermatitis, it can slide towards a medicinal claim; and if it is presented as controlling micro-organisms on the skin, it can touch the biocidal regime — a different legal pathway entirely, not just a CPSR. Our guide to what qualifies as a cosmetic product under EU law explains where that borderline sits. Keep your nappy-cream claims in cosmetic territory, and make sure your assessor sees the exact wording you intend to use.
The testing a baby product actually needs
Baby products sit in the most demanding microbiological category. Under the relevant ISO standards (ISO 17516 for microbiological limits and ISO 11930 for preservation-efficacy testing), products intended for children under three fall into the stricter limit category, with the lowest permitted total viable counts and absence of specified pathogens. That makes two pieces of laboratory work effectively non-negotiable:
- A preservative-efficacy (challenge) test, which deliberately inoculates the product with test organisms to prove the preservative system can control contamination introduced during real-world use. For a baby product you want it to meet the more stringent acceptance criterion, not merely scrape a pass. Our preservative efficacy (challenge) test service covers this.
- Microbiological limits testing to confirm the finished batch meets the tighter counts for the under-three category. The same principle applies to any water-containing artisan product — see how it plays out for makers in handmade soap safety and microbiological testing.
On top of microbiology, baby products should carry dermatological test evidence — a human tolerance study under dermatological supervision — and, for anything used near the eyes such as a baby shampoo, ocular (eye) tolerance data. These underpin any “gentle” or “suitable for sensitive skin” claim, which must itself meet the EU common criteria for cosmetic claims. Stability and packaging-compatibility data round out the picture, since a formula that destabilises can lose its preservation. For a fuller map of the lab work, see our overview of cosmetic laboratory testing requirements.
What extra data the safety assessor requires
Pulling the threads together, here is how an infant product differs from a general adult product across the assessment — and what each difference obliges you to supply.
| Consideration | Why it is stricter for babies | What is required |
|---|---|---|
| Exposure & Margin of Safety | Low bodyweight and high surface-area-to-bodyweight ratio raise the systemic dose per kilogram; immature metabolism clears less. | Exposure recalculated with infant bodyweight and use pattern; conservative MoS, with added uncertainty factors where data is thin. |
| Dermal absorption | Thinner, more permeable stratum corneum lets more penetrate. | Worst-case or measured absorption values; lower ingredient concentrations where MoS is tight. |
| Ingredient restrictions | Annex entries specifically exclude some substances (e.g. certain preservatives) for children under 3. | Full ingredient screening against Annexes II–VI at in-use levels; substitution of any restricted substance. |
| Fragrance & allergens | Higher sensitisation risk on immature skin. | Minimise or omit fragrance/essential oils; declare fragrance allergens per Regulation (EU) 2023/1545. |
| Microbiological quality | Vulnerable skin; Annex I flags under-3 products specifically. | Strictest microbiological limits plus a passing challenge test to the more stringent criterion. |
| Tolerance evidence | Infants cannot report irritation; occlusion (nappy area) worsens it. | Dermatological tolerance study, and ocular tolerance for eye-area or wash products. |
| Claims & category | Nappy/barrier claims can cross into medicinal or biocidal territory. | Claims kept cosmetic and substantiated; borderline check before launch. |
In practice, expect your assessor to ask for complete supplier documentation on every ingredient (specifications, certificates of analysis, allergen and impurity declarations), the challenge and microbiological reports, stability data, tolerance study reports and your final artwork and claims. The more you assemble up front, the smoother and quicker the sign-off.
Bringing it all together
A baby product is not a normal product with a softer label. Thinner skin, a higher surface-area-to-bodyweight ratio and immature metabolism make every exposure sum more conservative, Annex I demands specific attention to children under three, several ingredients are simply off the table, and the microbiological and tolerance testing bar is set high. Design for that from the first formulation draft and the compliance work becomes straightforward rather than a series of nasty surprises.
If you are developing lotions, oils, washes or nappy creams for infants, our Cosmetic Product Safety Report (CPSR) service handles the infant-specific exposure and Margin of Safety assessment, checks every ingredient against the relevant restrictions, and tells you which tests your formula needs before it goes to market — so you place a product you can stand behind on the most sensitive skin there is.
Frequently asked questions
Do baby cosmetics need a different CPSR from adult products?
They need the same type of report but a stricter assessment within it. The Annex I structure is identical, but for children — especially under three — the exposure and Margin of Safety are calculated with an infant’s low bodyweight and higher skin permeability, ingredient restrictions specific to young children apply, and more demanding microbiological and tolerance data is required. See the general structure in our CPSR Explained guide.
Why is the Margin of Safety lower for the same formula in a baby product?
Because the systemic exposure dose is higher. The Margin of Safety is the NOAEL divided by the estimated exposure per kilogram of bodyweight. Infants weigh far less and have proportionally more skin, so the same applied amount delivers a higher dose per kilogram — pushing the ratio down. Assessors may also add uncertainty factors where infant toxicology data is limited, which lowers the acceptable ingredient concentration further.
Which ingredients should be avoided in baby cosmetics?
Start with substances the Annexes restrict for children under three, such as certain preservatives, and remove them at the formulation stage. Beyond the legal minimum, minimise or avoid fragrance, essential oils and known allergens because immature skin sensitises more readily. You still need effective preservation, so the goal is a well-tolerated, age-permitted preservative system used at the lowest effective level rather than an unpreserved “natural” product.
Is a nappy or diaper cream always a cosmetic?
Not automatically — it depends on presentation and claims. A cream that protects, softens or maintains the skin is a cosmetic, but one presented to treat or prevent a condition like nappy-rash dermatitis can become a medicinal product, and one presented as killing micro-organisms on skin can touch the biocidal regime. Keeping claims within cosmetic language is essential; our guide to what qualifies as a cosmetic product under EU law explains where the line falls.
What laboratory testing do baby products need?
At minimum, a preservative-efficacy (challenge) test to prove the product resists contamination in use, microbiological limits testing to the strictest category applied to children under three, and dermatological tolerance evidence — plus ocular tolerance for anything used near the eyes such as a baby shampoo. Stability and packaging-compatibility data support the preservation. Our overview of cosmetic laboratory testing requirements sets out how these fit together.
What does “children under 3” mean for my assessment?
It is a defined vulnerable group singled out in Annex I of Regulation (EC) No 1223/2009. If a product is intended, labelled or reasonably foreseeably used on children under three, the safety assessor must give specific attention to its exposure and microbiological quality for that group — using conservative infant exposure assumptions and the strictest microbiological limits — even if the product is not marketed as a dedicated “baby” line.
